厄贝沙坦联合辛伐他汀治疗45例阵发性房颤的临床疗效
作者：李国富;周嘉琼;詹龙亮;杨洋;
Author：
收稿日期： 年卷（期）页码：2012,27(04):-471-474
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：阵发性房颤;厄贝沙坦;辛伐他汀;联合用药
Key words：
基金项目：
中文摘要
目的观察厄贝沙坦联合辛伐他汀治疗阵发性房颤的临床疗效。方法将80名患有阵发性心房颤动(房颤)的患者分为单用厄贝沙坦组和厄贝沙坦加用辛伐他汀组,随访1年,比较两组在第3、6、9、12个月时房颤的复发率以及治疗后的左心房内径。结果治疗后两组在第3、6个月时的房颤复发率无显著性差异(P>0.05),而在第9、12个月时,厄贝沙坦组的房颤复发率高于厄贝沙坦加用辛伐他汀组,且差异有统计学意义(P0.05);在第12个月时,厄贝沙坦组的左心房内径大于厄贝沙坦加用辛伐他汀组,且差异有统计学意义(P
参考文献
[1]Fuster V,Rydén LE,Cannom DS,et al.ACC/AHA/ESC2006guidelines for the management of patients with atrial fibrillation[J].Circulation,2006,114(7):e257-354.
[2]周自强,胡大一,陈捷,等.中国心房颤动现在的流行病学研究[J].中华内科杂志,2004,43(7):491-494.
[3]Braunwald E.Shattuck Lecture:Cardiovascular medicine at thetern of the millennium:Triumphs,concerns,and opportunities[J].N Engl J Med,1997,337:1360-1369.
[4]Roy D,Talajic M,Dorian P,et al.Amiodarone to prevent recur-rence of atrial fibrillation[J].N Engl J Med,2000,342:913-920.
[5]邓新桃,何倩,赵建祥,等.厄贝沙坦对器质性心脏病合并阵发性房颤的疗效[J].现代医学,2007,35(1):31.
[6]Fauchier L,Pierre B,Labriolle A,et al.Antiarrhythmic effect ofstatin therapy and atrial fibrillation:A meta-analysis of random-ized controlled trials[J].J Am Coll Cardiol,2008,51(8):828-835.
[7]Limón L,Rebollo JM,Madrid AH,et al.Angiotensin receptorblockar as adjunctive therapy for rhythm control in atrial fibrilla-tion results of the irbesartan-amiodarone trial[J].Cardiac Elec-trophysiol Rev,2003,7:242-245.
[8]李超,蒋勇,韦玉华,等.胺碘酮联合厄贝沙坦治疗阵发性房颤的临床观察[J].右江民族医学院学报,2011(02):151-153.
[9]Hadi HA,Mahmeed WA,Suwaidi JA,et al.Pleiotropic effects of statins in atrial fibrillation patients:The evidence[J].Vasc Health Risk Manag,2009,5(3):533-551.
[10]Tesfamariam B,Frohlich BH,Gregg RE,et al.Differential effects of pravastatin,simvastatin,and atorvastatin on Ca 2+release and vascu-lar reactivity[J].J Cardiovasc Pharmacol,1999,34(1):95-101.
[11]Bolotina V,Omelyanenko V,Heyes B,et al.Variations of mem-brane cholesterol alter the kinetics of Ca 2+-dependent K+channels and membrane fluidity in vascular smooth muscle cells[J].Pfulugers Arch,1989,415(3):262-268.
[12]Kumagai K,Nakashima H,Saku K.The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting in-flammation in a canine sterile pericarditis model[J].Cardiovasc Res,2004,62(1):105-111.
[13]Patti G,Chello M,Candura D,et al.Randomized trial of atorvasta-tin for reduction of postoperative atrial fibrillation in patients un-dergoing cardiac surgery:Results of the ARMYDA-3(Atovasta-tin for reducion of myocardial dysrhythmia after cardiac surgery)study[J].Circulation,2006,114(14):1455-1461.
[14]Burstein B,Nattel S.Atrial fibrosis mechanisms and clinical rele-vance in atrial fibrillation[J].J Am Coll Cardiol,2008,51:802-809.
【关闭】
